Author:
Toomer Gabriela,Burns Whitney,Melendez Monica,Garcia Liliana,Henry Gerelyn,Biancofiori Anthony,George Albert,Duffy Ciera,Chu Justin,Sides Morgan,Muñoz Melissa,Garcia Kelly,Nikolai-Yogerst Anya,Peng Xinjian,Westfall Landon,Baker Robert
Abstract
ABSTRACTAnimal models are used in preclinical trials to test vaccines, antivirals, monoclonal antibodies, and immunomodulatory drug therapies against SARS-CoV-2. However, these drugs often do not produce equivalent results in human clinical trials. Here, we show how different animal models infected with some of the most clinically relevant SARS-CoV-2 variants, WA1/2020, B.1.617.2/Delta, B.1.1.529/Omicron and BA5.2/Omicron, have independent outcomes. We show that in mice, B.1.617.2 is more pathogenic, followed by WA1, while B.1.1.529 showed an absence of clinical signs. Only B.1.1.529 was able to infect C57BL/6J mice, which lack the human ACE2 receptor. B.1.1.529-infected ACE2 mice had different T cell profiles compared to infected K18-hACE2 mice, while viral shedding profiles and viral titers in lungs were similar between the ACE2 and the C57BL/6J mice. These data suggest B.1.1.529 virus adaptation to a new host and shows that asymptomatic carriers can accumulate and shed virus. Next, we show how B.1.617.2, WA1 and BA5.2/Omicron have similar viral replication kinetics, pathogenicity, and viral shedding profiles in hamsters, demonstrating that the increased pathogenicity of B.1.617.2 observed in mice is host-dependent. Overall, these findings suggest that small animal models are useful to parallel human clinical data, but the experimental design places an important role in interpreting the data.IMPORTANCEThere is a need to investigate SARS-CoV-2 variants phenotypes in different animal models due to the lack of reproducible outcomes when translating experiments to the human population. Our findings highlight the correlation of clinically relevant SARS-CoV-2 variants in animal models with human infections. Experimental design and understanding of correct animal models are essential to interpreting data to develop antivirals, vaccines, and other therapeutic compounds against COVID-19.
Publisher
Cold Spring Harbor Laboratory
Reference30 articles.
1. Scientific Brief: SARS-CoV-2 Transmission | CDC. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html. Retrieved 7 October 2022.
2. Harvey WT , Carabelli AM , Jackson B , Gupta RK , Thomson EC , Harrison EM , Ludden C , Reeve R , Rambaut A , Peacock SJ , Robertson DL. 2021. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol https://doi.org/10.1038/s41579-021-00573-0.
3. Comparison of SARS-CoV-2 variant lethality in human angiotensin-converting enzyme 2 transgenic mice;Virus Res,2021
4. Becerra-Flores M , Cardozo T. 2020. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate. Int J Clin Pract 74.
5. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus